bluebird bio, Inc. is a biotechnology company. The Company focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases and cancer. It develops LentiGlobin for sickle cell disease (SCD) as a one-time treatment for patients with SCD, a hereditary blood disorder resulting from a mutation in the ß-globin gene that causes polymerization of hemoglobin proteins, resulting in abnormal red blood cell function. It builds an integrated product platform with therapeutic in a variety of indications based on its lentiviral gene addition platform, gene editing and cancer immunotherapy capabilities. Its programs in genetic disease include betibeglogene autotemcel; LentiGlobin gene therapy for sickle cell disease (SCD); and elivaldogene autotemcel. Its programs in oncology are focused on developing novel T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies.